4C Biomed combines cutting-edge science, real-world clinical insights and unique autologous cell systems (i.e. cancer and immune cells from the same patient) to drive the development of immuno-oncology therapies. Its lead drug is in a stage of IND-enabling studies and is planned to enter clinical Phase I in 2025. 4C Biomed’s technology leverages a uniquely sensitive, immunological-based screening platform, which not only identifies novel immuno-oncology targets but also promises to accelerate the journey from discovery to clinical application.